Home

Biotech

Broadband

B2B Internet

Europe 2001

Internet

Internet 
Architecture

Internet 
Infrastructure

Market 2000+

Oil Services

Pharmaceutical

Regional Bank

Retail

Semiconductor

Software

Telecom

Utilities

Wireless
GlaxoSmithKline PLC (NYSE:GSK)7/28/2010
most recent headlinesmore headlines:       
THURSDAY, JULY 29, 2010
7:00 AMIsis Earns $5 Million Milestone Payment From GSK for Designation of a Development Candidate to Treat an Undisclosed Rare and Serious Disease - PR Newswire
6:00 AMAptuit and Siena Biotech Announce Strategic Relationship in Italy - BusinessWire
TUESDAY, JULY 27, 2010
10:15 AMNCCN Receives $4 Million in Oncology Research Funding from GlaxoSmithKline - BusinessWire
9:05 AMGlaxoSmithKline to enforce new customer compensation system for US sales professionals - M2
MONDAY, JULY 26, 2010
6:44 PMGlaxoSmithKline, Johnson & Johnson, Pfizer, AstraZeneca and More Present at the 6th Compound Management & Integrity Conference in Philadelphia, PA - BusinessWire
3:00 PMGlaxoSmithKline to Implement New Compensation Program for U.S. Sales Professionals - PR Newswire
THURSDAY, JULY 22, 2010
12:26 PMNPC Welcomes GlaxoSmithKline as New Member - PR Newswire
8:30 AMShionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference - PR Newswire
WEDNESDAY, JULY 21, 2010
3:00 PMActavis Receives Approval of Bupropion HCl SR 100mg and 200mg in the U.S. - PR Newswire
1:12 PMPharmaceutical, Biotech and Guidance Agencies including GlaxoSmithKline, Noven Pharmaceuticals Inc., Roche Carolina, Pfizer, Eli Lilly, Abbott and More Will Convene to Discuss the Latest in PAT & QbD Initiatives - BusinessWire


Quotes delayed at least 15 minutes. Market data provided by Interactive Data.
Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

HOLDRS Defined |  HOLDRS Outstanding  |  FAQ  |  Proxies by email  |  Investment Strategies
Spin-Offs & Changes  |  Current Trading  |  Download a Prospectus  |  Site Map

Merrill Lynch, Pierce, Fenner & Smith Incorporated is a registered broker-dealer and a wholly-owned subsidiary of Bank of America Corporation.
Securities Products: Are Not FDIC Insured • Are Not Bank Guaranteed • May Lose Value.

The information in this Internet site is directed at, and is intended for distribution to, and for use by, persons in the U.S. only, and is not intended for distribution to or use by any person in any other jurisdiction. Merrill Lynch does not warrant the accuracy or completeness of any price, tax, cost basis, or other information on this site, or any investment, tax or other benefits associated with HOLDRS.

The information on HOLDRSSM contained in this Internet site is solely for informational purposes and does not constitute either an offer to sell or the solicitation of an offer to buy HOLDRS. This information on HOLDRS is not, and is not intended to be, a complete discussion of all material information you should know about HOLDRS. If you are considering whether to purchase a HOLDRS security, you should carefully read the relevant prospectus prior to making a purchase. You should not rely on the information contained in this Internet site. Please view Terms of Use and Legal Notices for additional important legal information and the terms and conditions governing your use of this site.

U.S. Patent Pending.
HOLDRS and HOLding Company Depositary ReceiptS are service marks of Merrill Lynch & Co., Inc.

© Copyright 2000, Merrill Lynch, Pierce, Fenner & Smith Incorporated. Member, Securities Investor Protection Corporation (SIPC). All rights reserved.